Swedish Cancer Biotech Oasmia Narrows Range For IPO

Published: Sep 16, 2015

Oasmia Pharmaceutical, which is developing formulations of widely-used cancer drugs for humans and dogs, narrowed the range and added a co-manager for its IPO on Tuesday.

The Uppsala, Sweden-based company plans to raise up to $23 million by offering ADSs at a price range of $5.75 to $7.75. The company will command a market cap of approximately $200 million after the offering, based on current trading on Nasdaq Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).

Help employers find you! Check out all the jobs and post your resume.

Back to news